Brilacidin Tetrahydrochloride is an investigational polymer-based antibiotic, structurally modeled after host defense peptides, currently under evaluation for the treatment of serious Gram-positive bacterial… Read more
Brilacidin Tetrahydrochloride is an investigational polymer-based antibiotic, structurally modeled after host defense peptides, currently under evaluation for the treatment of serious Gram-positive bacterial infections, including those caused by methicillin-resistant Staphylococcus aureus. As this novel compound undergoes clinical development, high-quality reference standards are essential for the rigorous analytical testing and quality control of the active pharmaceutical ingredient. Pharmaceutical laboratories utilize this range of related compounds, including non-pharmacopeial impurities and metabolites, to facilitate precise method validation and sensitive impurity profiling. Furthermore, the inclusion of stable isotope labelled compounds enables accurate quantification in complex matrices, such as biological samples, allowing researchers to monitor pharmacokinetics and metabolic pathways. These analytical tools support the comprehensive characterization of the drug substance and its degradation products, ensuring compliance with evolving regulatory standards during the drug development lifecycle.